p38 MAPK
The p38 MAPK family consists of highly conserved proline-directed serine-threonine protein kinases that are activated in response to a number many growth factors, cytokines, and chemotactic substances, such as vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), PDGF, TNF, interleukins, lipopolysaccharide (LPS) and formyl-methionyl-leucyl-phenylalanine (fMLP). It is well known that p38 is involved in inflammation, apoptosis, cardiomyocyte hypertrophy and cell differentiation.
The p38 MAPK family is composed of four proteins: p38α (encoded by the gene Mapk14), p38β (Mapk11), p38γ (Mapk12), and p38δ (Mapk13). Their coding genes have a distinct tissue distribution and they appear differentially expressed, being Mapk14 the most highly expressed. p38 MAPKs are substrates for three MAP2K (MKK6, MKK3, and MKK4). The contribution of each of these MAP2K to p38 MAPKs activation depends on the stimulus and the cell type. The MAP3Ks that lead to p38 MAPKs activation are ASK1, DLK1, TAK1, TAO1, TAO2, TPL2, MLK3, MEKK3, MEKK4, and ZAK1.
p38 MAPK Isoform Specific Products
All Product Categories
-
p38 MAPK Inhibitors
(846)
View all products
-
p38 MAPK Agonists
(6)
View all products
-
p38 MAPK Antagonists
(2)
View all products
-
p38 MAPK Activators
(228)
View all products
-
p38 MAPK Modulators
(21)
View all products
-
p38 MAPK p53 Inhibitors
(2)
View all products
-
p38 MAPK Inducers
(15)
View all products
-
p38 MAPK Degraders
(3)
View all products
-
p38 MAPK Control
(1)
View all products
-
p38 MAPK Ligands
(2)
View all products
-
AKT Serine/Threonine Kinase 1 (AKT1) Proteins
(3)
View all products
-
p38 MAPK Related Products (1217)
Related Products (1217)
-
Recombinant Proteins (3)
-
Antibodies (20)
-
p38 MAPK Isoform Comparison
-
TIC10g
0 ImagesTIC10g is a dual inhibitor for toll-like receptor 7 and 9 (TLR7 and TLR9), which inhibits TLR7 and TLR9 mediated TNF-α release in mouse macrophages (IC50 is 14.5 μM and 6.5 μM) and human B lymphocytes (IC50 is 7.69 μM and 11.5 μM). TIC10g inhibits the activation of NF-κB and MAPK, and exhibits anti-inflammatory activity against systemic lupus erythematosus and rheumatoid arthritis .
-
Dual Cathepsin L/JAK-IN-1
0 ImagesDual Cathepsin L/JAK-IN-1 (Compound A8) is a dual inhibitor of Cathepsin L (CTSL) and JAK, with IC50 values of 0.68 μM, 337.1 nM, 5.251 nM, 27.29 nM, and 172.6 nM for CTSL, JAK1/2/3, and TYK2, respectively. Dual Cathepsin L/JAK-IN-1 effectively blocks the activation of the MAPK, NF-κB, and JAK/STAT signaling pathways, leading to significant anti-inflammatory therapeutic effects. Dual Cathepsin L/JAK-IN-1 can be used in research on acute lung injury (ALI).
-
Dihydrocaffeic acid (Standard)
0 ImagesSynonyms: 3,4-Dihydroxy-benzenepropanoic acid (Standard)Ditalimfos (Standard) is the analytical standard of Ditalimfos. This product is intended for research and analytical applications. Ditalimfos is an organophosphate fungicide. Ditalimfos is mainly used in agriculture to control fungal diseases of crops. Ditalimfos can be used for fungal resistance studies and risk assessment of residues in the environment.
-
Mianserin-d3
0 ImagesSynonyms: Mianserine-d3Mianserin-d3 is the deuterium labeled Mianserin (HY-B0188). Mianserin (Mianserine) is an orally active H1 receptor antagonist. Mianserin can activate κ-opioid receptor and octopamine receptor. Mianserin increases ERK1/2 and CREB phosphorylation, and antagonizes full κ-opioid agonist and Dynorphin A (HY-P1333)-induced MAPK phosphorylation. Mianserin modulates social and exploratory behaviour, raises electroconvulsive thresholds. Mianserin can be used for the research of neurological disease, such as depression and epilepsy.
-
Fulvestrant (S enantiomer)
0 ImagesCat. No.: HY-13636ACAS No.: 1316849-17-8Synonyms: ICI 182780 (S enantiomer); ZD 9238 (S enantiomer); ZM 182780 (S enantiomer)Fulvestrant (ICI 182780; ZD 9238) S enantiomer is the S-enantiomer of Fulvestrant (HY-13636), a potent estrogen receptor inhibitor. Fulvestrant binds to and blocks the estrogen receptor, promotes its degradation, and thereby inhibits receptor dimerization, nucleocytoplasmic shuttling and transcriptional activity. Fulvestrant effectively blocks estrogen signaling, MAPK pathway activation and ER-regulated protein expression. Fulvestrant induces apoptosis, inhibits the proliferation of breast cancer and prolactinoma cells, and reduces the mineralization level, alkaline phosphatase activity and osteocalcin expression of preosteoblasts. Prenatal exposure to Fulvestrant impairs ovarian follicular development and causes ovarian structural damage. Fulvestrant has been widely used in studies related to breast cancer, prolactinoma and other conditions.
-
SMU-14a
0 ImagesCat. No.: HY-176192SMU-14a is a selective Toll-like receptor 3 (TLR3) inhibitor wirh an IC50 of 0.18 μM. SMU-14a reduces phosphorylation of p65, ERK, and TBK1 via NF-κB, MAPK, and IRF3 signaling pathways. SMU-14a inhibits IL-6 secretion in mouse peritoneal macrophages, downregulates TNF-α in human peripheral blood monocytes and decreases serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels. SMU-14a can be used for the research of acute hepatitis.
-
Norbergenin
0 ImagesNorbergenin is a polyphenolic isocoumarin derivative. Norbergenin acts as a non-competitive inhibitor of bovine adrenal tyrosine hydroxylase (TH) with a Ki value of 69.6 μM. Norbergenin inhibits lipopolysaccharide-induced inflammatory responses in macrophages by suppressing the activation of NF-κB, MAPK and STAT3, as well as blocking metabolic reprogramming. Norbergenin inhibits aluminum chloride-induced oxidative stress and apoptosis and restores neurocognitive parameters. Norbergenin scavenges ROS through multiple mechanisms and protects cell membranes from lipid peroxidation damage. Norbergenin can be used in research related to Alzheimer's disease, peptic ulcer and arthritis.
-
IMC-EB10
0 ImagesCat. No.: HY-P991641Purity: 98%Synonyms: LY3012218IMC-EB10 (LY3012218) is an anti-FLT3 monoclonal antibody. IMC-EB10 binds to FLT3 with high affinity (Kd = 158 pM) and blocks the binding of FLT3 ligand to FLT3 (IC50 ≈ 10 nM), thereby inhibiting MAPK, STAT5, and PI3K/Akt signaling in leukemia cells. IMC-EB10 can enhance the anti-leukemic effect of Methotrexate (HY-14519) and inhibit leukemias expressing wild-type or ITD-mutated FLT3 receptors. IMC-EB10 prolongs the survival of acute lymphoblastic leukemia (ALL) cells and primary leukemia samples and reduces engraftment in non-obese diabetic/severe combined immunodeficiency patients. IMC-EB10 is indicated for leukemia research.
-
Gaultherin
0 ImagesGaultherin is an orally active non-steroidal anti-inflammatory agent. Gaultherin selectively inhibits NF-κB, MAPK, COX-2 (IC50 = 0.35 mg/mL), LOX (IC50 = 0.56 mg/mL) and HYAL (IC50 = 28.58 μg/mL) to exert anti-inflammatory, antipyretic and analgesic effects. Gaultherin exhibits modest direct antioxidant capacity, greater in cell-based models. Gaultherin does not affect COX-1 so that avoids the common gastrointestinal side effects of Aspirin (HY-14654).
-
MAPK14 Human Pre-designed siRNA Set A
0 ImagesCat. No.: HY-RS08107MAPK14 Human Pre-designed siRNA Set A contains three designed siRNAs for MAPK14 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
-
Withaphysalin A
0 ImagesWithaphysalin A is a withanolide compound with anti-inflammatory and antioxidant activities. Withaphysalin A inhibits LPS (HY-D1056)-induced nuclear translocation of NF-κB p65, as well as phosphorylation of STAT3, ERK, JNK and p38 MAPK. Withaphysalin A upregulates the expression of HO-1. Withaphysalin A inhibits LPS-induced production of NO, PGE2, IL-1β, IL-6 and TNF-α. Withaphysalin A downregulates LPS-induced expression of iNOS and COX-2. Withaphysalin A interacts with B-cell activating factor protein (BAFF) to exert inhibitory effects. Withaphysalin A exhibits ELOVL6 inhibitory activity. Withaphysalin A can be used in the research of inflammatory diseases, nephrotic syndrome and chronic myeloid leukemia.
-
Gamma-glutamylcysteine TFA (Standard)
0 ImagesCat. No.: HY-113402ARCAS No.: 283159-88-6Synonyms: γ-Glu-Cys TFA (Standard)Gamma-glutamylcysteine (TFA) (Standard) is the analytical standard of Gamma-glutamylcysteine (TFA). This product is intended for research and analytical applications. Gamma-glutamylcysteine TFA (γ-Glu-Cys TFA) is an orally active, blood-brain barrier permeable dipeptide. Gamma-glutamylcysteine TFA activates AMPK, SIRT1, IL-4/STAT6, AC/cAMP/PI3K, IGF-1R/IRS1/PI3K, and Nrf2 signaling pathways; it inhibits NF-κB, JAK1/STAT1/3, MAPKs, cadmium-induced p38 MAPK, JNK, and PI3K/Akt signaling pathways. Gamma-glutamylcysteine TFA regulates macrophage polarization, modulates the trafficking of CD36 and GLUT4, induces glutathione synthesis, improves metabolic dysfunction, reduces lipid deposition, ameliorates glucose homeostasis, inhibits apoptosis (Apoptosis), stabilizes mitochondria, suppresses lipid peroxidation, iron accumulation and ferroptosis (Ferroptosis), reduces ds-HMGB1 levels, reverses mechanical hyperalgesia, and alleviates hepatic lipid droplet formation. Gamma-glutamylcysteine TFA is applicable to research related to inflammatory bowel disease, type 2 diabetes, cadmium-induced neurotoxicity, Alzheimer's disease, cerebral ischemia/reperfusion injury, neuropathy, and alcoholic liver disease.
-
PD 169316 (Standard)
0 ImagesPD 169316 (Standard) is the analytical standard of PD 169316 (HY-10578). This product is intended for research and analytical applications. PD 169316 is a potent, cell-permeable and selective p38 MAP kinase inhibitor, with IC50 of 89 nM. PD169316 selectively inhibits the kinase activity of the phosphorylated p38 without hindering upstream kinases to phosphorylate p38. PD169316 shows antiviral activity against Enterovirus71. PD169316 shows antiviral activity against Enterovirus71.
-
Mianserin hydrochloride (Standard)
0 ImagesSynonyms: Org GB 94 (Standard)Mianserin hydrochloride (Org GB 94) (Standard) is the analytical standard of Mianserin hydrochloride. This product is intended for research and analytical applications. Mianserin hydrochloride is an orally active H1 receptor antagonist. Mianserin hydrochloride can activate κ-opioid receptor and octopamine receptor. Mianserin hydrochloride increases ERK1/2 and CREB phosphorylation, and antagonizes full κ-opioid agonist and Dynorphin A (HY-P1333)-induced MAPK phosphorylation. Mianserin hydrochloride modulates social and exploratory behaviour, raises electroconvulsive thresholds. Mianserin hydrochloride can be used for the research of neurological disease, such as depression and epilepsy.
-
(Z)-2-(Oleoyloxy)propane-1,3-diyl dipalmitate
0 ImagesSynonyms: 1,3-Dipalmitoyl-2-oleoylglycerol; ?1,3-Palmitin-2-Olein; TG(16:0/18:1/16:0)(Z)-2-(Oleoyloxy) propane-1,3-diyl dipalmitate (1,3-Dipalmitoyl-2-oleoylglycerol) is an orally active PTP1B inhibitor with an IC50 of 31.01 μM and a Ki of 16.36 μM. (Z)-2-(Oleoyloxy) propane-1,3-diyl dipalmitate also inhibits α-glucosidase with an IC50 of 163.31 μM. It inhibits phosphorylation of p38 MAPK, activates the PI3K/Akt/CREB pathway, and exhibits antioxidant, anti-apoptosis and anti-inflammatory activities, as well as inhibits peroxynitrite-mediated albumin nitration. (Z)-2-(Oleoyloxy) propane-1,3-diyl dipalmitate can be used in studies related to cerebral ischemia-reperfusion injury and diabetes.
-
DL-Syringaresinol
0 ImagesDL-Syringaresinol ((±)-Syringaresinol), a lignin, inhibits UVA-induced upregulation of MMP-1 by suppressing MAPK/AP-1 signaling in human HaCaT keratinocytes and dermal fibroblasts (HDFs). DL-Syringaresinol has antiphotoaging properties against UVA-induced skin aging. DL-Syringaresinol exhibits weak antimycobacterial activity against Mycobacterium tuberculosis H37Rv.
-
Sorafenib-d4
0 ImagesSynonyms: Bay 43-9006-d4Sorafenib-d4 (Bay 43-9006-d4) is the deuterated-labeled Sorafenib (HY-10201). Sorafenib (Bay 43-9006) is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib inhibits tumor growth and metastasis in mouse and rat models. Sorafenib can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma.
-
Atraric acid (Standard)
0 ImagesAtraric acid (Standard) is the analytical standard of Atraric acid. This product is intended for research and analytical applications. Atraric acid (Methyl atrarate) is a specific androgen receptor (AR) antagonist with anti-inflammatory and anticancer effects. Atraric acid represses the expression of the endogenous prostate specific antigen gene in both LNCaP and C4-2 cells. Atraric acid can also inhibit the synthesis of NO and cytokine, and suppress the MAPK-NFκB signaling pathway. Atraric acid can be used to research prostate diseases and inflammatory diseases[1][2].
